Loading...
Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy
Accumulating preclinical evidence indicates that Toll-like receptor (TLR) agonists efficiently boost tumor-targeting immune responses (re)initiated by most, if not all, paradigms of anticancer immunotherapy. Moreover, TLR agonists have been successfully employed to ameliorate the efficacy of various...
Saved in:
| Published in: | Oncoimmunology |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Taylor & Francis
2015
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4839356/ https://ncbi.nlm.nih.gov/pubmed/27141345 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1088631 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|